Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
about
Targeting MAPK Signaling in Age-Related Macular DegenerationConfronting the Care Delivery Challenges Arising from Precision MedicineThe biological complexity of colorectal cancer: insights into biomarkers for early detection and personalized careEstablishment and characterization of a novel uterine carcinosarcoma cell line, TU-ECS-1, with mutations of TP53 and KRAS.A synthetic-lethality RNAi screen reveals an ERK-mTOR co-targeting pro-apoptotic switch in PIK3CA+ oral cancersOverexpression of c-Jun contributes to sorafenib resistance in human hepatoma cell lines.Optimal Cut-Off Values of Lymph Node Ratio Predicting Recurrence in Papillary Thyroid Cancer.Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma.Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview.Reviving the guardian of the genome: Small molecule activators of p53.Role Played by Signalling Pathways in Overcoming BRAF Inhibitor Resistance in Melanoma.Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.Mek activity is required for ErbB2 expression in breast cancer cells detached from the extracellular matrix.The AP-1 transcription factor FOSL1 causes melanocyte reprogramming and transformation.Signal transduction in L-DOPA-induced dyskinesia: from receptor sensitization to abnormal gene expression.
P2860
Q26744185-D933A6CA-7E11-409B-8B3E-473571E3CD60Q26747282-5C86338C-7ED9-49EB-9E9A-0DBE1856C4A8Q28066460-74B76FB0-7F1F-46E1-9A56-417BD812AC1BQ33364318-B4E5F6B7-19F2-4E2A-9268-D7FB1413674CQ35925179-F3EFC43D-FABA-4A84-869E-56759F052DC6Q36316437-F3F2EC09-9ECD-4A7B-8CCB-063709215FAEQ36566991-72EDA200-0714-4A51-A8A3-8F672E863C54Q38669765-D60BCA94-5BE6-4371-9D5A-EDE24A7E3C7BQ38714341-70AB30F3-B84D-4863-95FC-695673F7C5E0Q38989374-25A77ADC-6A7C-4D12-977D-9F261D739BE0Q39205536-6C1061C2-1942-470F-97C7-9F0151A38FC5Q39434922-10D2CA45-0B28-4ED4-97D7-814203F00898Q41098492-EAB27C21-1504-421E-ADDC-FA6104B6A31CQ47102400-1EA0C674-3503-444C-AA39-080E414CE6CEQ48176997-F0933FFF-9C31-4964-8ADD-42CF6705F716Q49357267-BAFE4763-9B23-404D-AD33-3E09984CF1AD
P2860
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Stamping out RAF and MEK1/2 to ...... threat to anticancer therapy.
@en
type
label
Stamping out RAF and MEK1/2 to ...... threat to anticancer therapy.
@en
prefLabel
Stamping out RAF and MEK1/2 to ...... threat to anticancer therapy.
@en
P2860
P356
P1433
P1476
Stamping out RAF and MEK1/2 to ...... g threat to anticancer therapy
@en
P2093
K Strebhardt
P2860
P2888
P304
P356
10.1038/ONC.2015.329
P407
P577
2015-09-14T00:00:00Z
P5875
P6179
1026149417